Urology
Volume 75, Issue 5 , Pages 1149-1155 , May 2010

Efficacy and Tolerability of Fesoterodine in Men With Overactive Bladder: A Pooled Analysis of 2 Phase III Studies

  • Sender Herschorn

      Affiliations

    • Sunnybrook Health Sciences Centre, Division of Urology, Toronto, Ontario, Canada
    • Corresponding Author InformationReprint requests: Sender Herschorn, M.D., Sunnybrook Health Sciences Centre, 2075 Bayview Ave, Toronto, ON M4N3M5, Canada
    • ,
  • J. Stephen Jones

      Affiliations

    • Glickman Urological & Kidney Institute, Cleveland Clinic, Beachwood, Ohio
    • ,
  • Matthias Oelke

      Affiliations

    • Hannover Medical School, Department of Urology, Hannover, Germany
    • ,
  • Scott MacDiarmid

      Affiliations

    • Alliance Urology Specialists, Greensboro, North Carolina
    • ,
  • Joseph T. Wang

      Affiliations

    • Pfizer Inc, New York, New York
    • ,
  • Zhonghong Guan

      Affiliations

    • Pfizer Inc, New York, New York

Received 10 June 2009 ,Accepted 1 September 2009.

References 

  1. Abrams P, Artibani W, Cardozo L, et al. Reviewing the ICS 2002 terminology report: the ongoing debate. Neurourol Urodyn. 2006;25:293
  2. Chapple CR, Roehrborn CG. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol. 2006;49:651–659
  3. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20:327–336
  4. Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50:1306–1315
  5. Oelke M, Baard J, Wijkstra H, et al. Age and bladder outlet obstruction are independently associated with detrusor overactivity in patients with benign prostatic hyperplasia. Eur Urol. 2008;54:419–426
  6. Hyman MJ, Groutz A, Blaivas JG. Detrusor instability in men: correlation of lower urinary tract symptoms with urodynamic findings. J Urol. 2001;166:550–552
  7. Lee JY, Kim HW, Lee SJ, et al. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int. 2004;94:817–820
  8. Machino R, Kakizaki H, Ameda K, et al. Detrusor instability with equivocal obstruction: a predictor of unfavorable symptomatic outcomes after transurethral prostatectomy. Neurourol Urodyn. 2002;21:444–449
  9. Kaplan SA, Roehrborn CG, Dmochowski R, et al. Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia. Urology. 2006;68:328–332
  10. Roehrborn CG, Abrams P, Rovner ES, et al. Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence. BJU Int. 2006;97:1003–1006
  11. Dmochowski R, Abrams P, Marschall-Kehrel D, et al. Efficacy and tolerability of tolterodine extended release in male and female patients with overactive bladder. Eur Urol. 2007;51:1054–1064
  12. Kaplan SA, Roehrborn CG, Rovner ES, et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. J Am Med Assoc. 2006;296:2319–2328
  13. Kaplan SA, Roehrborn CG, Chancellor M, et al. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. BJU Int. 2008;102:1133–1139
  14. Rovner ES, Kreder K, Sussman DO, et al. Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms. J Urol. 2008;180:1034–1041
  15. Athanasopoulos A, Gyftopoulos K, Giannitsas K, et al. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol. 2003;169:2253–2256
  16. Yang Y, Zhao XF, Li HZ, et al. Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study. Chin Med J [Engl]. 2007;120:370–374
  17. Chapple C, Herschorn S, Abrams P, et al. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. Eur Urol. 2009;56:534–543
  18. Kaplan SA, Walmsley K, Te AE. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol. 2005;174:2273–2276
  19. MacDiarmid SA, Peters KM, Chen A, et al. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. Mayo Clin Proc. 2008;83:1002–1010
  20. Abrams P, Kaplan SA, De Koning Gans HJ, et al. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol. 2006;175:999–1004
  21. Michel MC. Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome. Expert Opin Pharmacother. 2008;9:1787–1796
  22. Chapple C, van Kerrebroeck P, Tubaro A, et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol. 2007;52:1204–1212
  23. Nitti V, Dmochowski R, Sand P, et al. Efficacy, safety, and tolerability of fesoterodine in subjects with overactive bladder. J Urol. 2007;178:2488–2494
  24. Kelleher CJ, Tubaro A, Wang JT, et al. Impact of fesoterodine on quality of life: pooled data from two randomized trials. BJU Int. 2008;102:56–61
  25. Khullar V, Rovner ES, Dmochowski R, et al. Fesoterodine dose response in subjects with overactive bladder syndrome. Urology. 2008;71:839–843
  26. Colman S, Chapple C, Nitti V, et al. Validation of treatment benefit scale for assessing subjective outcomes in treatment of overactive bladder. Urology. 2008;72:803–807
  27. Kelly CE. Evaluation of voiding dysfunction and measurement of bladder volume. Rev Urol. 2004;6(Suppl 1):S32–S37
  28. Gomez A, Martos F, Bellido I, et al. Muscarinic receptor subtypes in human and rat colon smooth muscle. Biochem Pharmacol. 1992;43:2413–2419
  29. Peters TJ, Donovan JL, Kay HE, et al. The International Continence Society “Benign Prostatic Hyperplasia” Study: the bothersomeness of urinary symptoms. J Urol. 1997;157:885–889
  30. Martín-Merino E, García-Rodríguez LALuján Massó-González E, et al. Do oral antimuscarinic drugs carry an increased risk of acute urinary retention?. J Urol. 2009;182:1442–1448

 This study was funded by Schwarz BioSciences GmbH and Pfizer Inc.

PII: S0090-4295(09)02529-1

doi: 10.1016/j.urology.2009.09.007

Urology
Volume 75, Issue 5 , Pages 1149-1155 , May 2010

Article Tools

* Image Usage & Resolution